Characterization of binding of raltegravir to plasma proteins
about
Raltegravir as antiretroviral therapy in HIV/AIDS.Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study.
P2860
Characterization of binding of raltegravir to plasma proteins
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Characterization of binding of raltegravir to plasma proteins
@en
Characterization of binding of raltegravir to plasma proteins
@nl
type
label
Characterization of binding of raltegravir to plasma proteins
@en
Characterization of binding of raltegravir to plasma proteins
@nl
prefLabel
Characterization of binding of raltegravir to plasma proteins
@en
Characterization of binding of raltegravir to plasma proteins
@nl
P2093
P2860
P356
P1476
Characterization of binding of raltegravir to plasma proteins
@en
P2093
Anne-Marie Taburet
Aurélie Barrail-Tran
Caroline Barau
Catherine Fagard
Jean-Michel Molina
Valérie Furlan
Yazdan Yazdanpanah
P2860
P304
P356
10.1128/AAC.00625-13
P407
P577
2013-07-15T00:00:00Z